Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapeutics CEO Paul Romness and EVERSANA VP of ...

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, as Ben Hargreaves discovers, research ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

Bayer's quest to revamp its drug discovery engine continues apace, with the company's recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug ...

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The two partners ...